РУКОВОДСТВО ПО ДИАГНОСТИКЕ, ПРОФИЛАКТИКЕ И ЛЕЧЕНИЮ СЕРДЕЧНО-СОСУДИСТЫХ ОСЛОЖНЕНИЙ ПРОТИВООПУХОЛЕВОЙ ТЕРАПИИ.
Article Sidebar
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Main Article Content
Аннотация:
Достижения в лечении онкологических заболеваний привели к повышению выживаемости больных со злокачественными новообразованиями. В то же время противоопухолевая терапия сопряжена с риском развития побочных эффектов, среди которых сердечно-сосудистые осложнения занимают лидирующие позиции. Дисфункция левого желудочка и сердечная недостаточность, артериальная гипертония, ишемия миокарда, нарушения ритма сердца, тромбоэмболии и другие сердечно-сосудистые осложнения могут препятствовать проведению жизненно важной противоопухолевой терапии, снижать выживаемость и качество жизни больных.
Article Details
Как цитировать:
Библиографические ссылки:
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2018. www. goldcopd.org/.
Авдеев С.Н., Айсанов З.Р., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритмы принятия клинических решений. Пульмоно логия, 2017, 1: 13-20. /Avdeev SN, Aysanov ZR, Arkhipov VV, et al. National clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease: clinical decision support algorithm. Pulmonologiya, 2017, 1: 13-20.
Jones PW, Nadeau G, Small M, Adamek L. Metabolic and cardiovascular comorbidity in COPD patients classified using the GOLD 2011 assessment framework. Eur Resp J, 2012, 40: P988.
Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA, 1994, 272: 1497–1505.
Heindl S, Lehnert M, Criee CP et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Resp Crit Care Med, 2001, 164: 597–601.
Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8 year follow up of 14 719 initially healthy American women. Circulation, 2003, 107: 391–397.
Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation, 2003, 107: 1514–1519.
Curkendall SM, DeLuise C, Jones JK et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Am J Epid, 2006, 16: 63-70.
Engstrom G, Wollmer P, Hedblad B et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from «men born in 1914», Malmo, Sweden. Circulation, 2001, 103: 3086–3091.
Rosengren A, Wilhelmsen L. Respiratory symptoms and long term risk of death from cardiovascular disease, cancer and other causes in Swedish men Int J Epidemiol, 1998, 27: 962– 969.
Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356: 775-789.
Lange P, Marrott JL, Vestbo J et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. AJRCCM, 2012, 186(10): 975-981.
Wouters EFM, Cells MPM, Breyer MK, Rutten EPA, Graat-Verboom L, Spruit MA. Co-morbid manifestations in COPD. Resp Med, 2007: 3(4): 135–151.
Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest, 2016, 149(5): 1181–1196.
Rogliani P, Matera MG, Ora J et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J COPD, 2017, 12: 3469-3485.
Buhl R, Magder S, Bothner U et al. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Resp Med, 2017, 122: 58-66.
Calverly P, AnzuetoA, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Resp Med, 2018, 6(5): 337-344.
Wedzicha JA, Decramer M, Ficker JH et al. Analysis of Chronic Obstructive Pulmonary Disease Exacerbations with the Dual Bronchodilator QVA149 Compared with Glycopyrronium and Tiotropium (SPARK): a Randomized, Double-blind, Parallel-group Study. Lancet Resp Med, 2013, 1: 199–209.
Beeh K, Korn S, Beier J et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study. Resp Med, 2014, 108: 584-592.
Vogelmeier C, Bateman ED, Pallante J et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/ fluticasone in patients with COPD (ILLUMINATE): a randomized, double-blind, parallel group study. Lancet Resp Med, 2013, 1(1): 51-60.